arrow
P

Paolo A. Muraro

imperial college london
H指数:50
被引数:9,609

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

BEAM/ATG 或环磷酰胺/ATG 作为自体造血干细胞移植治疗多发性硬化中的预处理方案:EBMT 自身免疫性疾病工作组的一项回顾性分析

2025-09-290
OAAI
Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation

agresive MS和自体HSCT:欧洲血液与骨髓移植学会自身免疫疾病工作组代拟的综述

2025-07-070
PRE
Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)

自体造血干细胞移植治疗多发性硬化症在英国的应用:英国血液与骨髓移植及细胞治疗学会(BSBMTCT)20年回顾性分析活动及血液学结局

2025-06-110
OA
Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study
2025-04-190
OA
Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation
BRAIN
IF11.7
2024-07-180
PRE
Soluble CD27 is an intrathecal biomarker of T-cell-mediated lesion activity in multiple sclerosis

可溶性CD27是多发性硬化症中T细胞介导的病变活性的鞘内生物标志物

2024-04-121
OAAI
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee

自身免疫性疾病的创新细胞疗法: EBMT实践协调和指导委员会的专家立场声明和临床实践建议

2024-03-0111
OAAI
High Levels of Perivascular Inflammation and Active Demyelinating Lesions at Time of Death Associated with Rapidly Progressive Multiple Sclerosis Disease Course: A Retrospective Postmortem Cohort Study

死亡时高水平的血管周围炎症和活动性脱髓鞘病变与快速进展型多发性硬化病程相关: 一项回顾性死后队列研究

2024-01-127
OA
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
BRAIN
IF11.7
2022-06-0331
OAAI